Myriad wins US patent for p19 gene:
This article was originally published in Clinica
Myriad Genetics has received a US patent covering the DNA sequence of the tumour suppressor gene p19, otherwise known as MTS2. The patent also covers primers, probes and vectors relating to the use of the p19 gene in diagnostic and therapeutic products. The p19 gene is an important regulator of the p53 cancer pathway, said the Salt Lake City, Utah-based company. p53, the most common tumour suppressor gene, is mutated in over half of all types of cancer.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.